Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

The New England journal of medicine - 7 May 2026

Wolpin Brian M, Park Wungki, Garrido-Laguna Ignacio, Spira Alexander, Starodub Alexander, Sommerhalder David, Punekar Salman R, Barve Minal, Pelster Meredith, Herzberg Benjamin, Azad Nilofer S, Hecht Joel Randolph, Ou Sai Hong Ignatius, Lin Tong, Kar Sumit, Tao Lin, Vora Rashmi, Hegde Aparna, Aung Kyaw, Hong David S

Abstract excerpt

BACKGROUND: Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS. METHODS: In this phase 1-2 study, we evaluated daraxonrasib in patients with advanced solid tumors with...

Topics

Join the communities discussing this publication.

Administration, Oral
Antineoplastic Agents
Carcinoma, Pancreatic Ductal
Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pancreatic Neoplasms

Progression-Free Survival

Source

Identifiers

PMID: 42090791
DOI: 10.1056/NEJMoa2505783

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.PMID 42090791Read ↗

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.Semantic proximity Read ↗

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.Semantic proximity Read ↗

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

KRAS Inhibition in Pancreatic Cancer: Pooled Efficacy and Safety Signals from Early-Phase StudiesSemantic proximity Read ↗

Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?Semantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.Semantic proximity Read ↗

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.